Climb Bio Plans Multiple H2 2026 Budoprutug Data Readouts, Cash Runway to 2028
Climb Bio completed dosing in its budoprutug subcutaneous Phase 1 trial with data due H1 2026 and is enrolling budoprutug Phase 2 pMN, Phase 1b/2a ITP and Phase 1b SLE studies, all targeting H2 2026 data. The company has cash runway into 2028 while advancing its CLYM116 Phase 1 study.
1. Financial Position
Climb Bio enters 2026 with sufficient liquidity to fund its clinical programs through 2028, reducing near-term financing risk for ongoing trials.
2. Budoprutug Clinical Development
The subcutaneous Phase 1 study of budoprutug has completed dosing, with topline results expected in H1 2026. Simultaneously, a Phase 2 pMN trial, a Phase 1b/2a ITP study and global and China Phase 1b SLE trials are enrolling, with initial pharmacodynamic and efficacy readouts slated for H2 2026.
3. CLYM116 Anti-APRIL Program
Enrollment in the CLYM116 Phase 1 healthy volunteer study continues to assess safety, pharmacokinetics and pharmacodynamics, with data due mid-2026. A partner-led Phase 1/2 trial in IgAN patients has also initiated dosing under a single and multiple ascending dose design.